Senator has questions on Amgen anemia drug rebates
Reuters, April 4, 2008
Sen. Charles Grassley is questioning Amgen Inc. regarding allegations that some doctors received higher rebates on purchases of the company's anti-anemia drug Aranesp. In a statement, Grassley said there were concerns doctors were profiting by getting reimbursements from the government and private insurers that were higher than their actual cost for Aranesp. The drug is currently under scrutiny for safety concerns.
- Providers Lag as Consumers Set Agenda
- ICD-10 Delay Alters Provider, Vendor Prep
- Esther Dyson Launches Population Health Challenge
- Crisis Spurs Healthcare Payment Reform in Arkansas
- Payment Reform Naysayers 'Better Wake Up'
- Look Beyond Nurse-Patient Ratios
- HIT Leaders Want Flexibility, Transparency from Next HHS Chief
- As Hospitalist Patient Loads Rise, So Do Hospital Costs
- Reduce Readmissions by Activating Patients to Do 'Self-Care'
- Advance Directives: Let's Make a Law